Gabica Tablet Uses, Dosage and Side Effects in Pakistan

What Is Gabica?

Gabica is a brand name for pregabalin, a medication that belongs to the gabapentinoid class of drugs. It works on the central nervous system and is prescribed for a range of conditions involving nerve-related pain, anxiety, and seizures. Pregabalin was originally developed by Pfizer and marketed globally as Lyrica. In Pakistan, several brands of pregabalin are available, with Gabica being one of the most commonly prescribed.

Pregabalin is classified as a controlled substance in many countries including the United States (Schedule V), the United Kingdom, and several others, due to its potential for dependence and misuse. In Pakistan, while regulatory enforcement varies, prescribing doctors increasingly recognise the abuse liability of pregabalin, and responsible prescribing is essential. It should only ever be obtained with a valid prescription from a PMDC-registered physician.

Quick Facts

How Does Gabica Work?

Pregabalin binds to the alpha-2-delta (α2δ) subunit of voltage-gated calcium channels in the central nervous system. By binding to this subunit, it reduces the influx of calcium into nerve terminals. This in turn decreases the release of several excitatory neurotransmitters — including glutamate, noradrenaline, and substance P — from overactive nerve cells.

The net result is a calming of hyperexcited neural circuits. In neuropathic pain, damaged nerves fire excessively, sending pain signals even when no painful stimulus is present. Pregabalin dampens this abnormal firing. In anxiety disorders, it reduces the overactivity of stress-response circuits. In epilepsy, it helps stabilise neuronal excitability and reduce seizure frequency when used alongside other anticonvulsants.

Pregabalin is well absorbed orally, reaching peak blood levels within about 1 hour. It is not metabolised by the liver to any significant degree — it is excreted essentially unchanged by the kidneys. This means liver disease does not affect its dosing, but kidney impairment requires dose reduction. The elimination half-life is approximately 6 hours, which is why it is typically dosed two or three times daily.

Gabica Uses in Pakistan

Neuropathic Pain — The Primary Indication

Neuropathic pain is pain caused by damage to or dysfunction of the nervous system itself, rather than by tissue injury. It is commonly described as burning, shooting, electric-shock-like, or stabbing sensations. In Pakistan, the most common causes of neuropathic pain include:

• Diabetic peripheral neuropathy — Pakistan has one of the world's highest diabetes rates, and many patients develop painful numbness and burning in the feet and hands over time
• Post-herpetic neuralgia — persistent burning pain after a shingles (herpes zoster) outbreak
• Sciatica and radiculopathy — nerve root compression from herniated discs in the spine
• Trigeminal neuralgia — intense, stabbing facial pain
• Post-surgical or post-traumatic neuropathic pain

Pregabalin is considered a first-line treatment for neuropathic pain by international guidelines (NICE, AAN, IASP). It has demonstrated efficacy in large randomised controlled trials, with a Number Needed to Treat (NNT) of approximately 4–7 for 50% pain reduction in diabetic neuropathy and post-herpetic neuralgia.

Fibromyalgia

Fibromyalgia is a chronic condition characterised by widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive difficulties ("fibro fog"). Pregabalin was the first drug approved by the US FDA specifically for fibromyalgia. It reduces pain, improves sleep quality, and can improve overall function in fibromyalgia patients. In Pakistan, fibromyalgia is underdiagnosed but increasingly recognised by rheumatologists and pain specialists.

Generalised Anxiety Disorder (GAD)

In Europe, pregabalin is approved for the treatment of Generalised Anxiety Disorder. It has demonstrated anxiolytic (anti-anxiety) effects comparable to benzodiazepines and SSRIs in clinical trials, with a faster onset of action than SSRIs (typically within the first week). Pakistani psychiatrists sometimes prescribe pregabalin for anxiety, particularly when SSRIs are not tolerated or when rapid anxiolytic effect is needed. However, the dependence risk means it should not be the first choice for most patients with anxiety, and benzodiazepine-dependent patients may be at higher risk of pregabalin misuse.

Epilepsy — Adjunctive Therapy

Pregabalin is approved as an add-on (adjunctive) treatment for partial-onset seizures with or without secondary generalisation in adults. It is not used as monotherapy for epilepsy. When standard anticonvulsants such as carbamazepine, valproate, or levetiracetam are not providing adequate seizure control, pregabalin may be added to the regimen. In Pakistan, neurologists at tertiary centres prescribe it in this role.

CRITICAL SAFETY WARNING: Dependence, Abuse and Withdrawal

Pregabalin is a controlled substance with recognised dependence and abuse potential. This is not a theoretical risk — it is well-documented in medical literature and increasingly observed in clinical practice worldwide, including in Pakistan where non-prescription access has led to misuse.

Key facts about pregabalin dependence:

• Physical dependence can develop within 2–4 weeks of regular use, even at therapeutic doses prescribed by a doctor
• Tolerance — the need for increasing doses to achieve the same effect — is common with prolonged use
• Withdrawal syndrome occurs in a significant proportion of patients upon abrupt discontinuation. Symptoms include: insomnia, headache, nausea, anxiety, excessive sweating, diarrhoea, tremor, agitation, and in rare but serious cases, seizures (even in patients who do not have epilepsy)
• Euphoric effects at higher doses make pregabalin attractive for recreational misuse. This is especially concerning when combined with opioids, benzodiazepines, or alcohol — combinations that significantly increase the risk of respiratory depression and death
• Patients with a history of substance use disorder (addiction to alcohol, benzodiazepines, opioids, or other drugs) are at substantially higher risk of pregabalin misuse

Rules for safe use:

• NEVER take Gabica without a valid prescription from your doctor
• NEVER increase the dose on your own — if the current dose is not working, consult your doctor
• NEVER stop Gabica abruptly — your doctor must taper (gradually reduce) the dose over at least 1 week
• NEVER share your medication with others
• NEVER combine Gabica with alcohol, benzodiazepines (Xanax, Valium), or opioids (tramadol, morphine) without explicit medical supervision — this combination can be fatal
• If you feel you need more medication than prescribed, or experience cravings, tell your doctor immediately

Gabica Dosage Guide

Dosing must always be individualised by your doctor based on the condition being treated, kidney function, and tolerance. Below are general guidelines — do not self-dose.

Important dosing rules:

• Gabica can be taken with or without food — food does not significantly affect absorption
• Take doses at evenly spaced intervals (e.g. morning and evening) to maintain steady blood levels
• If you miss a dose, take it as soon as you remember — but if it is almost time for the next dose, skip the missed one. Never double up.
• When discontinuing: your doctor MUST taper the dose gradually over at least 1 week. Do not stop abruptly.

Side Effects of Gabica

Common Side Effects

The following side effects are very common (affecting more than 10% of patients) and usually most pronounced during the first 1–2 weeks of treatment or after dose increases:

• Drowsiness / somnolence — the most common side effect; do not drive or operate machinery until you know how it affects you
• Dizziness — can increase fall risk, especially in elderly patients
• Weight gain — pregabalin increases appetite and can cause significant weight gain with long-term use (3–5 kg on average; more in some patients)
• Dry mouth
• Blurred vision
• Peripheral oedema (swelling of hands, ankles, feet)
• Difficulty concentrating / "brain fog"

Serious Side Effects — Seek Immediate Medical Attention

• Severe allergic reaction — facial swelling, difficulty breathing, widespread rash (rare but serious)
• Suicidal thoughts or mood changes — like all anticonvulsants, pregabalin carries a small but documented risk of increased suicidal ideation. Report any worsening depression, unusual mood changes, or suicidal thoughts to your doctor immediately
• Severe muscle pain or weakness — rare cases of rhabdomyolysis (muscle breakdown) have been reported
• Visual disturbance — loss of vision, blurred vision that does not resolve
• Breathing difficulty — especially if combined with opioids or CNS depressants

Who Should NOT Take Gabica

• Allergy to pregabalin — if you have had a previous allergic reaction to pregabalin or gabapentin
• Severe kidney disease — pregabalin is eliminated by the kidneys; dose must be reduced in renal impairment, and it may be contraindicated in severe cases
• History of substance abuse — patients with a history of alcohol, benzodiazepine, or opioid dependence are at significantly higher risk of pregabalin abuse and dependence. Your doctor must weigh risks very carefully.
• Pregnancy (Category D) — animal studies show birth defects; human data suggest a possible risk of major congenital malformations. Use only if clearly needed and no safer alternative exists. Women of childbearing age should use effective contraception.
• Breastfeeding — pregabalin is excreted in breast milk. The risk to the infant is unknown. Discuss with your doctor.
• Congestive heart failure — pregabalin can cause fluid retention and peripheral oedema, which may worsen heart failure

Drug Interactions

Pregabalin has relatively few pharmacokinetic drug interactions because it is not metabolised by the liver. However, pharmacodynamic interactions — additive sedation and CNS depression — are the major concern:

• Opioids (tramadol, morphine, codeine) — combined sedation; increased risk of respiratory depression and death. This combination is particularly dangerous.
• Benzodiazepines (Xanax, Valium, clonazepam) — additive sedation and dependence risk
• Alcohol — significantly worsens drowsiness, dizziness, and impairment. Avoid alcohol completely while taking Gabica.
• Other CNS depressants — antihistamines (diphenhydramine), sleep medications (zolpidem), certain antidepressants — all increase sedation
• ACE inhibitors (enalapril, ramipril) — rare reports of increased risk of angioedema when combined with pregabalin
• Thiazolidinediones (pioglitazone) — both cause weight gain and peripheral oedema; combination worsens both

Monitoring While on Gabica

Regular follow-up with your prescribing doctor is essential while taking Gabica:

• Pain or anxiety assessment — at every visit to determine whether the medication is effective and whether the dose needs adjustment
• Kidney function (serum creatinine / eGFR) — at baseline and periodically, especially in elderly patients or those with pre-existing kidney issues. Dose adjustment is required if kidney function declines.
• Weight monitoring — at each visit. Discuss dietary strategies if significant weight gain occurs.
• Mental health assessment — watch for signs of depression, suicidal ideation, or unusual behavioural changes, particularly in the first few months of treatment
• Signs of dependence — your doctor should assess for dose escalation, requests for early refills, or signs of misuse at every visit
• Vision — report any visual changes to your doctor promptly

Gabica in Pakistan — Availability and Cost

Gabica and other pregabalin brands are available at major pharmacy chains across Pakistan including Fazal Din & Sons, D.Watson, Shaheen Chemist, and thousands of local pharmacies in Karachi, Lahore, Islamabad, Peshawar, and other cities. Multiple brands are available:

• Gabica — one of the most commonly prescribed brands
• Lyrica (Pfizer) — the original brand; generally more expensive
• Pregabid, Nervia, Peglin — other locally manufactured brands

Approximate cost ranges from Rs. 15–40 per capsule depending on the strength and brand. A month's supply at a typical dose of 150 mg twice daily can cost Rs. 900–2,400. A valid prescription from a PMDC-registered doctor is required — and given the controlled nature of this drug, responsible dispensing is especially important.

Frequently Asked Questions